Researchers find low-dose PET/CT best imaging method for lymphoma
Low-dose PET/CT demonstrates the best sensitivity and specificity for initial staging of lymphoma, according to a study presented on Thursday at the RSNA meeting.
Low-dose PET/CT demonstrates the best sensitivity and specificity for initial staging of lymphoma, according to a study presented on Thursday at the RSNA meeting.
Dr. Immaculada Pinilla Fernandez, from the University Hospital La Paz in Madrid, Spain, and colleagues prospectively studied 108 consecutive patients with biopsy-proven non-Hodgkin's lymphoma as well as Hodgkin's lymphoma. The patients underwent initial staging with F-18 FDG-PET/CT that included a low-dose CT and a PET study followed by a full-dose, contrast-enhanced CT.
Low-dose PET/CT correctly classified lymphoma stage in 77.5% of patients, while PET correctly classified 65.6% and contrast-enhanced CT identified 63%. The researchers found the sensitivity and specificity of low-dose PET/CT to be 94.8% and 90.5%, respectively. The positive and negative predictive values were 93% and 92%. PET sensitivity and specificity was 90% and 86%. Sensitivity and specificity for CT was 88% and 90%.
Since low-dose PET/CT achieved the best sensitivity and specificity, radiation dose could be reduced and use of intravenous iodinated contrast material could be avoided in patients with lymphoma, Fernandez said.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
